Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06726811 · ClinicalTrials.gov registry record

Droperidol and QTc Interval Changes in ED Patients

A clinical trial of Emergency Department Patient and QTc Intervals Changes, sponsored by CHRISTUS Health.

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT06726811 is a study of Emergency Department Patient and QTc Intervals Changes that is actively recruiting participants, run by CHRISTUS Health. The registered enrollment target is 500 participants, above the 247-participant average among 5 other Emergency Department Patient trials with a reported enrollment target (102% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06726811, a study of Emergency Department Patient and QTc Intervals Changes, is actively recruiting participants, sponsored by CHRISTUS Health.

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval. Hypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of IV Droperidol during an emergency department visit.

Interventions

  • DRUG Droperidol injection

Study Locations (1)

Texas

  • CHRISTUS Spohn Hospital Corpus Christi-Shoreline - Corpus Christi

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2024-10-17
Est. Completion 2026-09-30

Sponsor

CHRISTUS Health

12 total trials

What the Registry Record Tells You About NCT06726811

The ClinicalTrials.gov registry entry for NCT06726811 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 247-participant average among 5 other Emergency Department Patient trials with a reported enrollment target (102% higher). The listed sponsor is CHRISTUS Health, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Emergency Department Patient appearing as the primary indexed condition, and to 1 intervention - of which Droperidol injection is the first listed.

NCT06726811 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT06726811 about?

NCT06726811 is a clinical study titled "Droperidol and QTc Interval Changes in ED Patients". Objectives To assess the association of low-dose Droperidol administration in the emergency department with changes in the QTc interval. Hypothesis Our study is designed to test the null hypothesis that there will be no clinically significant change in QTc interval after administration of 2.5mg of ...

What is the current status of trial NCT06726811?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-10-17. Estimated completion is 2026-09-30.

What conditions does trial NCT06726811 study?

This clinical trial studies the following conditions: Emergency Department Patient, QTc Intervals Changes.

What interventions are being tested in trial NCT06726811?

The interventions under investigation include: Droperidol injection (DRUG).

Who is sponsoring clinical trial NCT06726811?

This trial is sponsored by CHRISTUS Health, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06726811 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Emergency Department Patient

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.